RecruitingPhase 1/2

Effect of Honey For CIN II

Netherlands60 participantsStarted 2024-12-30

Plain-language summary

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 18-40 years * Primary CIN II confirmed histologically in the biopsy on colposcopic examination * Sufficient mastery of the Dutch language Exclusion Criteria: * Simultaneous abnormality in columnar epithelial cells (AIS). * Hr-HPV negative cytology * Immunosuppressant use/Autoimmune disease (HIV, CVID) * History of cervical carcinoma or previous treatment for CIN (LLETZ or imiquimod) * Pregnancy or the intention to become pregnant during the study period * Legal incompetence * Known allergies to honey

What they're measuring

Clearance of hr-HPV

Timeframe: 6 months

Trial details

NCT IDNCT06219018

SponsorZuyderland Medisch Centrum

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-01

Contact for this trial

Jordy Mongula, dr.

+31621872080 j.mongula@zuyderland.nl

View on ClinicalTrials.gov More Cervical Intraepithelial Neoplasia-II trials